Clonal T cell populations scarcely impair patients with rheumatic diseases: a prospective long-term follow up study.

Autor: Gernert M; Department of Medicine II, Rheumatology and Clinical Immunology, University Hospital of Würzburg, Oberdürrbacher Str. 6, D-97080, Würzburg, Germany. gernert_m1@ukw.de., Müller T; Chair of Bioinformatics, University of Würzburg, Am Hubland, D-97074, Würzburg, Germany., Schweiker L; Department of Medicine II, Rheumatology and Clinical Immunology, University Hospital of Würzburg, Oberdürrbacher Str. 6, D-97080, Würzburg, Germany., Schmalzing M; Department of Medicine II, Rheumatology and Clinical Immunology, University Hospital of Würzburg, Oberdürrbacher Str. 6, D-97080, Würzburg, Germany., Fröhlich M; Department of Medicine II, Rheumatology and Clinical Immunology, University Hospital of Würzburg, Oberdürrbacher Str. 6, D-97080, Würzburg, Germany., Nagler LK; Department of Medicine II, Rheumatology and Clinical Immunology, University Hospital of Würzburg, Oberdürrbacher Str. 6, D-97080, Würzburg, Germany., Strunz PP; Department of Medicine II, Rheumatology and Clinical Immunology, University Hospital of Würzburg, Oberdürrbacher Str. 6, D-97080, Würzburg, Germany., Labinsky H; Department of Medicine II, Rheumatology and Clinical Immunology, University Hospital of Würzburg, Oberdürrbacher Str. 6, D-97080, Würzburg, Germany., Schwaneck EC; Medizinisches Versorgungszentrum Rheumatologie und Autoimmunmedizin Hamburg GmbH, Mönckebergstraße 27, D-20095, Hamburg, Germany.
Jazyk: angličtina
Zdroj: Arthritis research & therapy [Arthritis Res Ther] 2024 Dec 11; Vol. 26 (1), pp. 210. Date of Electronic Publication: 2024 Dec 11.
DOI: 10.1186/s13075-024-03444-0
Abstrakt: Background: Clonal T cell populations are frequently detected in patients with rheumatic diseases. The relevance of this finding is often uncertain, as the clinical spectrum can range from being asymptomatic to T cell leukemia. Former studies suggested that certain anti-rheumatic drugs might influence the course of the clonal T cell populations.
Methods: A prospective long-term follow up study was performed including patients with rheumatic diseases and clonal T cell populations. Clinical features, adverse events, especially infections and cytopenias, and immunosuppressive medication were assessed. T cell populations were characterized by polymerase chain reaction, flow cytometry and stimulated cell cultures.
Results: 28 Patients with rheumatoid arthritis, spondyloarthritis, or giant cell arteritis were prospectively followed for up to 7.6 years. Severe infections or cytopenias (10.7% autoimmune neutropenias) were rare. The clonal T cell populations mostly persisted over time, the tumor burden decreased in the long-term. The cytokine secretion in stimulated T cell cultures did not differ in the subgroup of RA patients with versus without clonal T cells.
Conclusion: Clonal T cell populations in patients with rheumatic diseases are common, but are rarely harmful. Feared neutropenia, infections or progression into T cell leukemia could not be detected in the long-term in our cohort.
Competing Interests: Declarations. Ethics approval and consent to participate: This study was approved by the local ethics committee of the University of Würzburg. All data was generated in compliance with the declaration of Helsinki. Consent for publication: Not applicable. Competing interests: MG received travel grants, compensation for advisory boards or speaker’s fees from AbbVie, Amgen, AstraZeneca, Eli Lilly, Hexal, Janssen, Novartis, Pfizer, Takeda, UCB. TM none. LS none. MS received speaker’s fees, travel grants, research funding, or compensation for consultancies or board memberships from AbbVie, Actelion, AstraZeneca, BMS, Boehringer/Ingelheim, Celgene, Chugai/Roche, Eli Lilly, Genzyme, Gilead, Hexal/Sandoz, Janssen-Cilag, MSD, Novartis, Pfizer, Sanofi Pasteur, Takeda (Shire), UCB. MF received speaker’s fees, travel grants or compensation for board memberships from AbbVie, Novartis, Janssen, and Eli Lilly. LN received travel grant from AbbVie, Medac, and UCB. P-PS received travel grants from AbbVie, Lilly, Euroimmun, Galapagos, and Janssen-Cilag and research founding from Chugai. HL received travel grants, compensation for advisory boards or speaker’s fees from Janssen, Novartis, Abbvie, Pfizer, Alfasigma, Boehringer/Ingelheim, Celltrion and UCB. ECS received speaker’s fees, travel grants, research funding, or compensation for consultancies or board memberships from AstraZeneca, Boehringer-Ingelheim, Janssen, Chugai, Takeda, AbbVie, Novartis, Pfizer, Galapagos, GSK, Amgen, Medac, Otsuka, UCB.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: